Look out Rexulti, Axsome's Auvelity has its nod for Alzheimer's agitation

1st May 2026 Uncategorised 0

Four years after gaining FDA approval for Auvelity to treat major depressive disorder, Axsome Therapeutics has tacked on a second nod in the United States for the first-in-class medicine to treat agitation associated with Alzheimer’s disease.

More: Look out Rexulti, Axsome's Auvelity has its nod for Alzheimer's agitation
Source: fierce